The procedure was performed at Tucson Medical Center, Arizona, US. Credit: MAD.vertise/ shutterstock.com.

US-based medical device company Laplace Interventional has successfully completed the first-in-human procedure in an early feasibility study (EFS) with its TTVR system.

The EFS clinical protocol is approved by the US Food and Drug Administration (FDA) and the procedure aims to evaluate the safety and technical feasibility of the Laplace TTVR system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This procedure was performed at Tucson Medical Center by Dr Thomas Waggoner and Dr George Makdisi from the US Heart and Vascular Institute, along with Dr Pradeep Yadav from Piedmont Heart Institute in attendance as a clinical proctor.

The patient who underwent the transcatheter tricuspid valve replacement was discharged and is currently recovering.

Waggoner said: “We are proud to be the first medical centre in the world to successfully implant a patient with Laplace Interventional’s cutting-edge new technology to treat tricuspid regurgitation. Thanks to the FDA’s dedication to the EFS programme, we are able to offer our patients new options for TTVR as early as possible through studies such as this.”

The TTVR system is intended to reduce or eliminate the effects of tricuspid regurgitation (TR) in adults who have severe or more symptomatic TR despite medical therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is specifically designed to offer a less invasive alternative to open-heart surgery by delivering the replacement valve through the patient’s vasculature.

Laplace Interventional founder and CEO Ramji Iyer said: “The successful completion of the FIH procedure in the US EFS study marks a significant milestone for Laplace’s technology and in understanding its potential to benefit a significant number of patients with tricuspid regurgitation.”

Last year, Laplace Interventional successfully closed a $12.9m Series B financing round to advance its strategy for its first-in-human trial of its transcatheter valve system.

The financing was co-led by ShangBay Capital and Features Capital, with additional participation from Engage Venture Partners, and JWC Ventures.